Eton Pharmaceuticals (ETON) Revenue (2019 - 2025)

Eton Pharmaceuticals has disclosed Revenue across 7 years of filings, most recently posting $21.3 million for Q4 2025.

• Revenue for Q4 2025 came in at $21.3 million, up 82.72% year-over-year; the trailing twelve-month figure through Dec 2025 was $64.5 million (up 65.22% YoY), and the FY2025 annual result was $80.0 million, up 104.94% from the prior year.
• Revenue came in at $21.3 million for Q4 2025 at Eton Pharmaceuticals, down from $22.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $29.8 million in Q4 2023 to a low of $775000.0 in Q3 2021.
• The 5-year median for Revenue is $8.2 million (2022), against an average of $9.9 million.
• Across the five-year window, Revenue jumped 203200.0% in 2021 and sank 81.71% in 2022, its largest moves.
• Eton Pharmaceuticals' Revenue stood at $6.1 million in 2021, then jumped by 39.47% to $8.5 million in 2022, then soared by 250.69% to $29.8 million in 2023, then slumped by 60.92% to $11.6 million in 2024, then surged by 82.72% to $21.3 million in 2025.
• The last three Revenue figures came in at $21.3 million (Q4 2025), $22.5 million (Q3 2025), and $18.9 million (Q2 2025), per Business Quant data.